SureTrader Advertisement Advertisement Advertisement
Home > Boards > US Listed > Biotechs >

Mast Therapeutics, Inc. (MSTX)

Add MSTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BooDog, okaly
Search This Board:
Last Post: 10/10/2015 1:00:09 AM - Followers: 320 - Board type: Free - Posts Today: 1

Mast Therapeutics
 We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.  Webcast from Cowen Healthcare Conference 03/03/14  Piper Jaffray Healthcare Conference 12/03/13 : 30 minute audio presentation by CEO B. Culley  NEW    12th Annual Bio-Investor Conference 10/08/13: 32 page PDF NEW 
Blog Update from CEO B. Culley 12/12/13  NEW  Data From Proof of Concept Study in Heart Failure 

2015 Biotech Conference Presentation Slides: January 12th 2015.

A service of the U.S. National Institutes of Health


  • Make bi


Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

This study is currently recruiting participants.
Verified July 2013 by Mast Therapeutics, Inc.
Mast Therapeutics, Inc.
Information provided by (Responsible Party):
Mast Therapeutics, Inc. Identifier:
First received: November 27, 2012
Last updated: July 22, 2013
Last verified: July 2013

The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.

Condition Intervention Phase
Vaso-occlusive Crisis
Sickle Cell Disease
Drug: ANX-188
Drug: Saline
Phase 3
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
Resource links provided by NLM:
Further study details as provided by Mast Therapeutics, Inc.:
Primary Outcome Measures:
  • Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease. [ Time Frame: Study participants will be followed for the duration of hospital stay, an expected average of 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Re-hospitalization rate for VOC [ Time Frame: Hospital discharge to 14 days post-discharge ] [ Designated as safety issue: No ]
    Occurence of acute chest syndrome [ Time Frame: Randomization to 120 hours after randomization ] [ Designated as safety issue: No ]
Estimated Enrollment: 388
Study Start Date: May 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ANX-188
ANX-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
Drug: ANX-188
Placebo Comparator: Saline
Saline administered as a continuous infusion for up to 49 hours
Drug: Saline


Please refer to this study by its identifier: NCT01737814

Contact: Mast Therapeutics Call Center 1-888-965-1238  

Responsible Party: Mast Therapeutics, Inc. Identifier: NCT01737814     History of Changes
Other Study ID Numbers: ANX-188-01
Study First Received: November 27, 2012
Last Updated: July 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Mast Therapeutics, Inc.:
sickle cell disease
vaso-occlusive crisis

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn processed this record on July 25, 2013





MST-188 (lead product candidate)

MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.


2013 Activities

Event Timing

Initiate tQT/QTc Study Completed

Secure Orphan Designation for MST-188 for SCD in EU Completed

Activate First Site in Phase 3 Study Completed

File New Patent Applications Completed

Dose First Subject in Phase 3 Study Completed

Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met

Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA

Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14

2014 Activities

Event Timing

Present Data From Nonclinical Proof-of-Concept Study In Heart Failure  Q1 '14  Data Released 01/06/14'Showed Significant Statistical Improvement"

Initiate Phase 2 Study in ALI Q1 '14 Initiated

Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER

Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule

Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14

Request Orphan Designation for ALI in EU Q2 '14  Application Submitted

Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated

Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14

Report Results from Phase 2 Study of AIR001 in PAH Q3 '14 Positive Top line Data released 9/8/14

Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14 CRADA with US Military Initiated Q3 '14

Receive protocol from FDA for Phase 2 Heart Failure Study Q4'14 FDA Approves Heart Failure Study 12/9/14

2015 Event Schedule

Initiate dosing Phase2a study in AIR001 Q1 '15.  INITIATED 2/4/15

Nonclinical Study EMBOLIC STROKE Data Q1 '15:  POSITIVE DATA RELEASED 2/11/15

Report nonclinical data for repeat dose on Vepoloxamer in Heart Failure Q1 '15 POSITIVE DATA RELEASE 03/02/15

Phase 2 Study HEART FAILURE Initiate Enrollment Q2 '15 INITIATED 3/23/15

EPIC EXTENSION STUDY (Repeat Exposure) Initiate Enrollment 1st Half '15 INITIATED 5/26/15 

Phase 2a Study of AIR001 (WHO GROUP 2) in HFpEF Preliminary Data 2nd Half '15

Phase 2 Study Heart Failure Interim Safety Analysis 2nd Half '15



EPIC Top Line Data Q1 2016


Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug


Schedule 13D and 13G filings submitted since 09/30/14

  Filing Company Date of
Total Reported
Shares Owned
Shares Reported
on 13F
  Baker Bros LLC 12/31/14 4,774,434 4,774,434
  BVF Inc. 3/31/15 7,241,600 7,241,600!
SC 13G FRANKLIN RESOURCES INC 02/04/15 11,946,100 11,946,100
Reported via Event Date Name Ticker Shares * Change % of Portfolio
13F MPM Asset Management     MSTX 2,551,851    
13F Vanguard Group     MSTX 3,382,483    
13F Proquest Associates                                                                                                                                                                                                      MSTX.                        2,551,851




Contact Information

P: 858-552-0866    F: 858-552-0876
General Inquiries

Investor Relations Contact

Business Development Contact

Careers Contact




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MSTX News: Current Report Filing (8-k) 10/07/2015 12:51:43 PM
MSTX News: Current Report Filing (8-k) 09/30/2015 08:31:42 AM
MSTX News: Mast Announces Amendment To Loan And Security Agreement With Hercules Technology Growth Capital 09/30/2015 08:00:00 AM
MSTX News: Mast Announces Presentation Of Results Of Nonclinical Study Of Vepoloxamer In Chronic Heart Failure At The HFSA's Annual Scie... 09/28/2015 08:00:00 AM
MSTX News: Mast Therapeutics To Host Analyst & Investor Day On October 7, 2015 09/23/2015 08:00:00 AM
#13116  Sticky Note Upcoming Catalysts: Blinkx90 08/29/15 12:50:48 PM
#13413   Strangest "chart day" in months. From about 10:00 pray 10/10/15 01:00:09 AM
#13412   Rather be wrong and green than right and red! pray 10/09/15 08:59:55 PM
#13411   Support line is right at .49, held .495 BooDog 10/09/15 05:42:04 AM
#13410   Hate to say "you are right" ..... but pray 10/09/15 04:52:34 AM
#13409   I don't see this moving now until January Bobby Blue 10/09/15 03:57:55 AM
#13408   Seems like a bi-weekly burst where its up pray 10/08/15 11:51:16 PM
#13407   Thank you Red,you lost only a little battle. lux1 10/08/15 05:36:21 PM
#13406   Held support well. Added a few .51's. Lii's BooDog 10/08/15 03:20:33 PM
#13405   Just wished along with updating investors they had pray 10/08/15 01:26:49 PM
#13404   I have absolutely no expectation of this ever okaly 10/08/15 01:18:13 PM
#13403   Hope they are able to break the $1.00 pray 10/08/15 01:14:46 PM
#13402   CANACCORD: Maintains buy rating, $3 PT okaly 10/08/15 12:24:29 PM
#13401   ROTH CAPITAL: Buy Reiterated (again....) okaly 10/08/15 12:05:32 PM
#13400   Absolutely Boo, the AIR001 comments were positive, I Rhodey Red 10/08/15 07:55:41 AM
#13399   So far EPIC is meeting end points performing BooDog 10/08/15 07:36:06 AM
#13398   Keeping to my word I have removed myself Rhodey Red 10/08/15 07:05:42 AM
#13397   Actually looked possible to break back into the BooDog 10/08/15 06:46:49 AM
#13396   All good brother....hopefully we will now get a Bobby Blue 10/08/15 05:51:58 AM
#13395   They were always talking to each other just pray 10/07/15 11:21:02 PM
#13394   Hopefully we have now seen the end of Bobby Blue 10/07/15 11:10:03 PM
#13393   Yeah, we were all so excited. wodehouse 10/07/15 09:14:17 PM
#13392   Why was it an utter embarrassment ? Kgs68 10/07/15 07:37:09 PM
#13391   Yeah, they are still deleting posts they don't lie, wodehouse 10/07/15 07:29:23 PM
#13389   Big buys today that's for sure, followed by Kgs68 10/07/15 06:37:00 PM
#13388   Although can not prove it he and another pray 10/07/15 06:05:01 PM
#13387   Much like every parent thinks their kid is okaly 10/07/15 05:33:22 PM
#13386   Yeah, wha' happened to printing .70? I guess wodehouse 10/07/15 05:06:07 PM
#13385   maybe one day. but i doubt okaly 10/07/15 03:58:45 PM
#13384   same ole same ole - maybe one day RNsidersbuying 10/07/15 03:46:38 PM
#13383   case in point, the 100k for sale at okaly 10/07/15 03:32:42 PM
#13382   I believe last R/S was 2010. If management pray 10/07/15 03:17:39 PM
#13381   with a share structure of about 1/3 of okaly 10/07/15 03:06:35 PM
#13380   Agree ... whole purpose of hub to begin pray 10/07/15 03:02:06 PM
#13379   these are circumstances that we need to consider; okaly 10/07/15 02:50:41 PM
#13378   Had same thoughts ... pray 10/07/15 02:46:37 PM
#13377   well, if 1m of the shares "bought" were okaly 10/07/15 02:43:54 PM
#13376   Welcome back to the boards bro ..... pray 10/07/15 02:36:41 PM
#13375   Over 1m shares were bought to bring this Kgs68 10/07/15 02:35:03 PM
#13374   If testing proves successful may have unbelievable product. pray 10/07/15 02:33:24 PM
#13373   GOODBYE RHODEY... okaly 10/07/15 02:21:39 PM
#13372   Great stats bro, in fact IMO on the pray 10/07/15 02:18:57 PM
#13371   $50M cash :-) & presentation BooDog 10/07/15 02:14:48 PM
#13370   Wall looking to move to mid .60's, let~r~rip! BooDog 10/07/15 01:19:19 PM
#13369   Big volume coming in with up ticks. nathanial 10/07/15 12:55:16 PM
#13365   Need more data and quite simply, needs more BooDog 10/07/15 11:58:58 AM
#13364   Use of the ignore button makes the board technicalwin 10/07/15 10:12:58 AM
#13363   I just saw a flying pig. nathanial 10/07/15 08:56:05 AM
#13362   Of course you are right, we may see Bobby Blue 10/07/15 08:49:44 AM
#13361   Seriously tho, you'll have to pose that question okaly 10/07/15 08:35:55 AM
#13360   I can see this pig in my portfolio. wodehouse 10/07/15 08:33:50 AM